1.63
0.00 (0.00%)
| Previous Close | 1.63 |
| Open | 1.63 |
| Volume | 210,070 |
| Avg. Volume (3M) | 263,009 |
| Market Cap | 120,022,768 |
| Price / Earnings (Forward) | 2.00 |
| Price / Sales | 2.59 |
| Price / Book | 3.19 |
| 52 Weeks Range | |
| Earnings Date | 14 Nov 2024 |
| Profit Margin | -38.62% |
| Operating Margin (TTM) | -18.01% |
| Diluted EPS (TTM) | -0.230 |
| Quarterly Revenue Growth (YOY) | -61.60% |
| Total Debt/Equity (MRQ) | 91.50% |
| Current Ratio (MRQ) | 1.34 |
| Operating Cash Flow (TTM) | -2.71 M |
| Levered Free Cash Flow (TTM) | 1.32 M |
| Return on Assets (TTM) | -10.27% |
| Return on Equity (TTM) | -43.49% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Protalix BioTherapeutics, Inc. | - | - |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | 5.0 |
| Technical Oscillators | 4.0 |
| Average | 1.13 |
|
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. It also develops PRX-102, a therapeutic protein candidate for the treatment of Fabry disease; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is based in Hackensack, New Jersey. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 14.53% |
| % Held by Institutions | 7.30% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Orin Green Financial, Llc | 30 Sep 2024 | 72,000 |
| Point72 Asia (Singapore) Pte. Ltd. | 30 Sep 2024 | 47,073 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 09 Dec 2024 | Announcement | Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce Validation of Variation Submission by European Medicines Agency for pegunigalsidase alfa |
| 14 Nov 2024 | Announcement | Protalix BioTherapeutics Reports Third Quarter 2024 Financial and Business Results |
| 07 Nov 2024 | Announcement | Protalix BioTherapeutics to Announce Third Quarter 2024 Financial and Business Results on November 14, 2024 |
| 25 Oct 2024 | Announcement | Protalix BioTherapeutics to Present Phase I PRX-115 Data in Late-Breaking Poster at ACR Convergence 2024 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |